Graves' Ophthalmopathy - Pipeline Review, H1 2018

  • ID: 4576081
  • Report
  • 35 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Genmab A/S
  • Novartis AG
  • Yuhan Corp
  • MORE
Graves' Ophthalmopathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2018, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights:

This latest pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Genmab A/S
  • Novartis AG
  • Yuhan Corp
  • MORE
Introduction

Report Coverage

Graves' Ophthalmopathy - Overview

Graves' Ophthalmopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Graves' Ophthalmopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graves' Ophthalmopathy - Companies Involved in Therapeutics Development

Enceladus Pharmaceuticals BV

Genmab A/S

Novartis AG

Yuhan Corp

Graves' Ophthalmopathy - Drug Profiles

pasireotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisolone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teprotumumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-BIO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-NCE3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Graves' Ophthalmopathy - Dormant Projects

Graves' Ophthalmopathy - Product Development Milestones

Featured News & Press Releases

Oct 25, 2017: Horizon Pharma Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease

Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease

Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Graves' Ophthalmopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H1 2018

Graves' Ophthalmopathy - Pipeline by Genmab A/S, H1 2018

Graves' Ophthalmopathy - Pipeline by Novartis AG, H1 2018

Graves' Ophthalmopathy - Pipeline by Yuhan Corp, H1 2018

Graves' Ophthalmopathy - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Graves' Ophthalmopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Enceladus Pharmaceuticals BV
  • Genmab A/S
  • Novartis AG
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll